PolarityTE Shares Advance 10% After Submitting Response to FDA_老虎社区_美港股上老虎

PolarityTE Shares Advance 10% After Submitting Response to FDA

Marketwatch2021-12-20

PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Kenny77
·2021-12-20
Please like
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1102069847?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-20 21:46","share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","id":"1102069847","market":"us","top_or_hot":-1,"title":"PolarityTE Shares Advance 10% After Submitting Response to FDA","media":"Marketwatch","content":"<div>\n<p>PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new ...</p>\n\n<a href=\"https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click\">网页链接</a>\n\n</div>\n","source":"market_watch","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PolarityTE Shares Advance 10% After Submitting Response to FDA </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolarityTE Shares Advance 10% After Submitting Response to FDA \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-20 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new ...</p>\n\n<a href=\"https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTE","symbol_name":"PolarityTE, Inc.","start_time":0,"source_url":"https://www.marketwatch.com/story/polarityte-shares-advance-10-after-submitting-response-to-fda-271640007099?mod=newsviewer_click","article_id":"1102069847","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102069847","pubTimestamp":1640007976,"columns":[],"sourceInfo":{"source_id":"market_watch","name":"华尔街大事件"},"weMediaInfo":null,"summary":"PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a com","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTE":"PolarityTE, Inc."},"translate_title":"向FDA提交回复后，PolarityTE股价上涨10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTE":0.9},"content_text":"PolarityTE Inc.'s shares jumped early Monday after the biotechnology company said it submitted a complete response to the U.S. Food and Drug Administration's clinical hold on an investigational new drug application for SkinTE with a proposed indication for chronic cutaneous ulcers.\nThe primary hold correspondence from the FDA related to certain chemistry, manufacturing and control items, including the assay to demonstrate the potency of SkinTE, the company said.\nIn premarket trading, the stock was 10% higher after ending Friday at 39 cents, down more than 40% since the end of last year.\nPolarityTE said that under FDA's standard practices and regulations, if the regulator agrees that the company's response is complete then a decision should be communicated within 30 days, subject to potential delays or other unforeseen circumstances.\n\"We believe that our response is robust and compelling in terms of addressing the issues raised by the FDA,\" Chief Executive Officer and President Richard Hague said.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":693622811,"gmtCreate":1640015329554,"gmtModify":1640015330237,"author":{"id":"3553679778150469","authorId":"3553679778150469","name":"Kenny77","avatar":"https://static.tigerbbs.com/77c5e512c4b7983d3f3075d8ec4c2f2d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3553679778150469","authorIdStr":"3553679778150469"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693622811","repostId":1102069847,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":24,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}